Cogent Biosciences, Inc. (COGT) Financial Statements (2026 and earlier)

Company Profile

Business Address 275 WYMAN STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments900,765,000390,890,000237,848,000245,661,000287,077,000335,519,000
Cash and cash equivalent312,012,000125,297,000127,598,000126,003,00098,165,00097,045,000
Short-term investments588,753,000265,593,000110,250,000119,658,000188,912,000238,474,000
Other undisclosed current assets9,590,0006,354,0007,160,0007,223,0009,395,0006,009,000
Total current assets:910,355,000397,244,000245,008,000252,884,000296,472,000341,528,000
Noncurrent Assets
Operating lease, right-of-use asset18,078,00018,591,00019,097,00019,599,00020,097,00020,580,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization5,457,0005,274,0005,850,0006,453,0006,467,0007,017,000
Long-term investments and receivables      10,029,000
Long-term investments      10,029,000
Restricted cash and investments416,000336,000    
Other noncurrent assets3,301,0004,488,0004,862,0004,862,0004,862,0004,862,000
Total noncurrent assets:27,252,00028,689,00029,809,00030,914,00031,426,00042,488,000
TOTAL ASSETS:937,607,000425,933,000274,817,000283,798,000327,898,000384,016,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,989,00027,812,00026,028,00018,305,00024,645,00023,094,000
Accounts payable9,504,00016,029,00016,625,00014,154,00012,013,00015,061,000
Accrued liabilities22,485,00011,783,0009,403,0004,151,00012,632,0008,033,000
Other undisclosed current liabilities31,964,00034,434,00032,394,00031,013,00031,065,00029,954,000
Total current liabilities:63,953,00062,246,00058,422,00049,318,00055,710,00053,048,000
Noncurrent Liabilities
Long-term debt and lease obligation222,895,00044,250,00043,949,000   
Long-term debt, excluding current maturities222,895,00044,250,00043,949,000   
Liabilities, other than long-term debt14,388,00016,973,00017,410,00015,485,00015,902,00016,309,000
Other liabilities33,0002,370,0002,359,0005,000  
Operating lease, liability14,355,00014,603,00015,051,00015,480,00015,902,00016,309,000
Total noncurrent liabilities:237,283,00061,223,00061,359,00015,485,00015,902,00016,309,000
Total liabilities:301,236,000123,469,000119,781,00064,803,00071,612,00069,357,000
Equity
Equity, attributable to parent, including:636,371,000302,464,000155,036,000218,995,000256,286,000314,659,000
Common stock161,000141,000114,000114,000110,000110,000
Additional paid in capital1,734,882,0001,280,128,0001,051,992,0001,042,021,0001,004,612,000994,609,000
Accumulated other comprehensive income (loss)355,000208,00013,000164,000447,000896,000
Accumulated deficit(1,188,420,000)(1,085,928,000)(1,004,998,000)(931,469,000)(859,483,000)(791,556,000)
Other undisclosed equity, attributable to parent89,393,000107,915,000107,915,000108,165,000110,600,000110,600,000
Total equity:636,371,000302,464,000155,036,000218,995,000256,286,000314,659,000
TOTAL LIABILITIES AND EQUITY:937,607,000425,933,000274,817,000283,798,000327,898,000384,016,000

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(99,493,000)(83,355,000)(75,582,000)(74,933,000)(73,734,000)(75,414,000)
Operating loss:(99,493,000)(83,355,000)(75,582,000)(74,933,000)(73,734,000)(75,414,000)
Nonoperating income (expense)(2,999,000)2,425,0002,053,0002,947,0005,807,0004,780,000
Investment income, nonoperating5,477,0003,887,0002,373,0002,952,0003,859,0004,779,000
Other nonoperating income (expense)(6,000)(3,000)(6,000)(5,000)1,948,0001,000
Interest and debt expense(5,408,000)(1,459,000)(314,000)   
Loss from continuing operations:(107,900,000)(82,389,000)(73,843,000)(71,986,000)(67,927,000)(70,634,000)
Other undisclosed net income5,408,000     
Net loss:(102,492,000)(82,389,000)(73,843,000)(71,986,000)(67,927,000)(70,634,000)
Other undisclosed net income attributable to parent  1,459,000314,000   
Net loss available to common stockholders, diluted:(102,492,000)(80,930,000)(73,529,000)(71,986,000)(67,927,000)(70,634,000)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(102,492,000)(82,389,000)(73,843,000)(71,986,000)(67,927,000)(70,634,000)
Other comprehensive income (loss)147,000195,000(151,000)(283,000)(449,000)1,088,000
Comprehensive loss:(102,345,000)(82,194,000)(73,994,000)(72,269,000)(68,376,000)(69,546,000)
Other undisclosed comprehensive income, net of tax, attributable to parent  1,459,000314,000   
Comprehensive loss, net of tax, attributable to parent:(102,345,000)(80,735,000)(73,680,000)(72,269,000)(68,376,000)(69,546,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: